A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis (CLARITY) (AIN457A2326)

June 24, 2016
Dermatology, Psoriasis
Natasha Mesinkovska, MD, PhD
UC Irvine Dermatology Clinical Research Center, 1001 Hewitt Hall, Irvine, CA 92697
The purpose of this research study is to find out if secukinumab (AIN 457) works better than another drug called ustekinumab in patients with plaque psoriasis.
Adults who have been diagnosed with psoriasis and who are not taking certain prohibited medications.
1 to 2 hour visits, with approximately eight visits over 12 months.
Taking part in this study may or may not make your health better. While researchers hope study medications will be more effective than other standard (usual) treatment, there is no proof of this yet. Both study medications can improve/treat your condition; you may benefit from participating in the study, but this cannot be guaranteed.
You will be compensated $50 a visit, not to exceed $400 for the entire study.
Patty Summerville, clinical research coordinator, Department of Dermatology